Semaglutide cuts death rates from cardiovascular disease and COVID-19

Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, finds.

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight

May 29, 2024

Primary Care Follow-Up After Emergency Surgery Tied to Fewer Readmissions

Among patients hospitalized for an emergency general surgery (EGS) condition, primary care follow-up within 30 days of discharge was associated with a significant reduction in

September 28, 2023

Benchstrength Closes $62M Early-Stage VC Fund with Healthcare Focus

What You Should Know: – Benchstrength, a New York City-based venture capital firm, has announced the close of its first $62M fund, focused on investing

December 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.